{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:46:12Z","timestamp":1787949972185,"version":"build-2784847793"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The first peanut oral immunotherapy (OIT) for children was approved by the US Food and Drug Administration (FDA) in 2020. While clinical efficacy is established, evidence on cost-effectiveness\u2014whether the benefits outweigh the costs and adverse effects\u2014remains limited. A variant of OIT, known as probiotic and peanut OIT (PPOIT), has shown similar efficacy in trials.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the cost-effectiveness of PPOIT, OIT, and no treatment.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This economic evaluation was conducted alongside a multicenter, randomized, placebo-controlled clinical trial in Australia between 2016 and 2019. Time horizon was 10 years, including 1.5 years of active treatment, 2 years of posttreatment follow-up, and 6.5 years of extrapolation. Data were analyzed from May 2024 to August 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n PPOIT and OIT.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Effectiveness was measured using remission achieved and patient quality-adjusted life years (QALYs) gained. Costs were evaluated from a health care payer perspective, including active treatment and adverse event costs, and were calculated in Australian dollars. Incremental cost-effectiveness ratios were estimated. Sensitivity analyses were conducted to capture uncertainty.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 201 children aged 1 to 10 years were recruited, 79 in PPOIT, 83 in OIT, and 39 in no treatment (mean [SD] age, 5.9 [2.8] years; 129 [64.2%] male). Over a 10-year horizon, mean (SD) cost per patient was A$3956 (A$67) for PPOIT (treatment, A$3579 [A$0]; adverse events, A$377 [A$67]), A$3582 [A$57] for OIT (treatment, A$3179 [A$0]; adverse events, A$402 [A$57]), and A$249 (A$87) for no treatment (treatment, A$0 [A$0]; adverse events, A$249 [A$87]). Mean (SD) annual remission was 34.1% (12.7%) for PPOIT, 35.1% (15.4%) for OIT, and 7.3% (8.1%) for no treatment. The total QALYs gained for PPOIIT, OIT, and no treatment were 0.096, 0.055, and 0, respectively. PPOIT was slightly more costly than OIT, achieved similar remission, and achieved better quality-of-life. Compared with no treatment, both treatments were more costly with minor risks, achieved higher remission (PPOIT, A$1384; 95% CI, A$1269-A$1415; and OIT, A$1199; 95% CI, A$1091-A$1217 per year of remission achieved, respectively), and improved quality of life (PPOIT, A$38\u202f435; 95% CI, A$31\u202f058-A$48\u202f668 and OIT, A$60\u202f840; 95% CI, A$49\u202f479-A$86\u202f531 per QALY gained, respectively).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This economic evaluation found that for remission, both PPOIT and OIT were cost-effective and good value compared with no treatment, with OIT associated with a larger effect size but no clinically meaningful difference. When QALYs are prioritized, PPOIT offers the best value. Key factors associated with cost-effectiveness were treatment product pricing and patient quality of life.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.2410","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:30:30Z","timestamp":1774020630000},"page":"e262410","source":"Crossref","is-referenced-by-count":2,"title":["Cost-Effectiveness of Oral Immunotherapy Treatments vs No Treatment for Peanut Allergy in Children"],"prefix":"10.1001","volume":"9","author":[{"given":"Li","family":"Huang","sequence":"first","affiliation":[{"name":"Child Health Economics Unit, The University of Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Lloyd","sequence":"additional","affiliation":[{"name":"Allergy Immunology, Murdoch Children\u2019s Research Institute, Victoria, Australia"},{"name":"Health Economics and Policy Evaluation Research, Monash Institute of Pharmaceutical Sciences, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Franz","sequence":"additional","affiliation":[{"name":"Child Health Economics Unit, The University of Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paxton","family":"Loke","sequence":"additional","affiliation":[{"name":"Allergy Immunology, Murdoch Children\u2019s Research Institute, Victoria, Australia"},{"name":"Department of Paediatrics, The University of Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"O\u2019Sullivan","sequence":"additional","affiliation":[{"name":"Immunology Department, Perth Children\u2019s Hospital, Western Australia, Australia"},{"name":"Division of Paediatrics, The University of Western Australia, Western Australia, Australia"},{"name":"The Kids Research Institute Australia, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gold","sequence":"additional","affiliation":[{"name":"Department of Allergy and Immunology, Women\u2019s and Children\u2019s Hospital, South Australia, Australia"},{"name":"Discipline of Paediatrics, Adelaide University, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Allergy and Immunology, Women\u2019s and Children\u2019s Hospital, South Australia, Australia"},{"name":"Discipline of Paediatrics, Adelaide University, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi L. K.","family":"Tang","sequence":"additional","affiliation":[{"name":"Allergy Immunology, Murdoch Children\u2019s Research Institute, Victoria, Australia"},{"name":"Department of Paediatrics, The University of Melbourne, Victoria, Australia"},{"name":"Department of Allergy and Immunology, The Royal Children\u2019s Hospital, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Dalziel","sequence":"additional","affiliation":[{"name":"Child Health Economics Unit, The University of Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"1","key":"zoi260103r1","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1542\/peds.2011-0204","article-title":"The prevalence, severity, and distribution of childhood food allergy in the United States.","volume":"128","author":"Gupta","year":"2011","journal-title":"Pediatrics"},{"key":"zoi260103r2","author":"Osborne","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"zoi260103r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2017.11.004","article-title":"Treatment for food allergy.","volume":"141","author":"Burks","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"zoi260103r8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaci.2014.11.034","article-title":"Administration of a probiotic with peanut oral immunotherapy: a randomized trial.","volume":"135","author":"Tang","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"zoi260103r9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2352-4642(17)30041-X","article-title":"Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial.","volume":"1","author":"Hsiao","year":"2017","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"zoi260103r10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2352-4642(22)00006-2","article-title":"Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.","volume":"6","author":"Loke","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"10","key":"zoi260103r11","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1111\/all.16262","article-title":"Two-year post-treatment outcomes following peanut oral immunotherapy in the Probiotic and Peanut Oral Immunotherapy-003 Long-Term (PPOIT-003LT) study.","volume":"79","author":"Loke","year":"2024","journal-title":"Allergy"},{"issue":"12","key":"zoi260103r12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-075521","article-title":"Cost-effectiveness analysis of probiotic peanut oral immunotherapy (PPOIT) versus placebo in Australian children with peanut allergy alongside a randomised trial.","volume":"13","author":"Huang","year":"2023","journal-title":"BMJ Open"},{"issue":"6","key":"zoi260103r13","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jaip.2017.04.016","article-title":"An economic analysis of a peanut oral immunotherapy study in children.","volume":"5","author":"Shaker","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"zoi260103r14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-035871","article-title":"Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy (PPOIT) in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapy (OIT) alone and with placebo (the PPOIT-003 study).","volume":"10","author":"Chebar Lozinsky","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"zoi260103r15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: a Report of the ISPOR CHEERS II Good Practices Task Force.","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"1","key":"zoi260103r16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1365-2222.2008.03120.x","article-title":"Development and validation of a self-administered food allergy quality of life questionnaire for children.","volume":"39","author":"Flokstra-de Blok","year":"2009","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"zoi260103r17","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/pai.13604","article-title":"Deriving health utility indices from a food allergy quality-of-life questionnaire.","volume":"32","author":"Chen","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"issue":"7","key":"zoi260103r18","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/all.16111","article-title":"Longitudinal peanut and Ara h 2 specific-IgE, -IgG4, and -IgG4\/-IgE ratios are associated with the natural resolution of peanut allergy in childhood.","volume":"79","author":"Parker","year":"2024","journal-title":"Allergy"},{"key":"zoi260103r19","first-page":"246","article-title":"Regression towards mediocrity in hereditary stature.","volume":"15","author":"Galton","year":"1886","journal-title":"J Anthropol Inst G B Irel"},{"issue":"4","key":"zoi260103r20","first-page":"2129","article-title":"Do old fallacies ever die?","volume":"30","author":"Friedman","year":"1992","journal-title":"J Econ Lit"},{"issue":"11","key":"zoi260103r21","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1001\/jamapediatrics.2013.2376","article-title":"The economic impact of childhood food allergy in the United States.","volume":"167","author":"Gupta","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"9715","key":"zoi260103r22","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0140-6736(09)61706-2","article-title":"Biological, clinical, and ethical advances of placebo effects.","volume":"375","author":"Finniss","year":"2010","journal-title":"Lancet"},{"key":"zoi260103r23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neuroscience.2015.08.017","article-title":"The placebo effect: from concepts to genes.","volume":"307","author":"Colagiuri","year":"2015","journal-title":"Neuroscience"},{"key":"zoi260103r5","volume-title":"Oral Immunotherapy and Viaskin\u00ae Peanut for Peanut Allergy: Effectiveness and Value","author":"Institute for Clinical and Economic Review (ICER)","year":"2019"},{"key":"zoi260103r6","author":"National Institute for Health and Care Excellence (NICE)"},{"key":"zoi260103r24","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1007\/978-3-031-17299-1_2246","volume-title":"Encyclopedia of Quality of Life and Well-Being Research","author":"Rowen","year":"2023"},{"key":"zoi260103r4","unstructured":"U.S. Food and Drug Administration (FDA). Palforzia. 2020. Accessed February 10, 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/allergenics\/palforzia"},{"key":"zoi260103r7","unstructured":"Australasian Society of Clinical Immunology and Allergy. Position Paper- Oral Immunotherapy for Food Allergy. 2024. Accessed February 13, 2026. https:\/\/www.allergy.org.au\/hp\/papers\/ascia-oral-immunotherapy-for-food-allergy"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2846737\/huang_2026_oi_260103_1773430283.20163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:30:32Z","timestamp":1774020632000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2846737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.2410","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]}}}